Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Scott C Weaver · WASHINGTON UNIVERSITY · 2024 · $3,960,456 — SUMMARY, Project 4 Alphaviruses regularly threaten global health, including long-established emerging viruses like Venezuelan equine encephalitis virus (VEEV, the most important of the encephalitic alphaviruses) and chikungunya virus (CHIKV, the most important arthritogenic alphaviruses) that unexpe…
Deborah H. Fuller · NORTHERN ARIZONA UNIVERSITY · 2024 · $363,131 — SUMMARY Coccidioidomycosis, also known as Valley Fever (VF) impacts residents in arid regions of the world including southwestern US, areas in South and Central America and in Mexico. Annual incidences are rising overall with estimated increases in recent years of more than 200% in some areas. In ad…
RUTH R MONTGOMERY · YALE UNIVERSITY · 2024 · $882,224 — Abstract We propose single-cell technologies to quantify multiparameter immune markers that provide in- depth single-cell data for analysis of immune responses to vaccination in our study cohorts. The shared platforms in this service core provide efficient and reproducible profiling in support of ou…
Steven Bradfute · ALBERT EINSTEIN COLLEGE OF MEDICINE · 2024 · $1,758,323 — In Project 2 (P2) we will use cutting-edge antigen engineering to refine vaccine antigen design strategies through iterative assessments of immunogenicity and protective efficacy to generate optimized vaccine immunogens against nairo-, hanta-, and paramyxoviruses. Our approach will establish a prote…
Richard Thomas Wyatt · SCRIPPS RESEARCH INSTITUTE, THE · 2024 · $236,999 — The elicitation of cross-neutralizing or broadly neutralizing Abs (bNAbs) to diverse HIV strains by Env vaccination remains a high priority for a broadly efficacious vaccine. The elicitation of bNAbs against conserved Env determinants remains elusive; however, the recent isolation of bNAbs to the …
ARTHUR Y KIM · MASSACHUSETTS GENERAL HOSPITAL · 2024 · $364,178 — Project Summary Translational research is critically dependent on availability of adequate specimens from well-defined clinical cohorts of patients. This Clinical Core builds and maintains such cohorts and facilitates a broad array of studies in human immunology. During the past three cycles of our …
Allie Greenplate · MASSACHUSETTS GENERAL HOSPITAL · 2024 · $364,389 — Project Summary/Abstract This CCHI U19 Program aims to determine how perturbations of the human immune system leads to do durable changes that impact future immune responses. Core C of this Immune Perturbation Study Group Program application will be central to the scientific efforts of this consorti…
Michael Scott Seaman · DANA-FARBER CANCER INST · 2024 · $300,463 — SUMMARY – CORE B Neutralizing Antibody Core Recent insights into HIV-1 Env structure and function are yielding a variety of new approaches aimed at designing more advanced and novel immunogens for eliciting broadly neutralizing antibodies (bnAbs) through vaccination. As improved immunogens enter det…
Barton F. Haynes · DUKE UNIVERSITY · 2024 · $393,526 — The Administrative Core will coordinate the scientific and administrative activities of this IPCAVD Program, ensuring that the Projects and Cores function well together. In particular, it will be responsible for managing the program's financial management, program management, and coordinating Projec…
Michael C. Abt · UNIVERSITY OF PENNSYLVANIA · 2024 · $359,600 — SUMMARY: PROJECT 3 - IMMUNOLOGY The quality of the host immune response to Clostridioides difficile infection is one of the strongest predictors of disease severity. Despite the protective capacity of the host immune response, the immune parameters that promote immunity remain poorly understood. App…
BALI PULENDRAN · STANFORD UNIVERSITY · 2024 · $539,703 — ABSTRACT – Project 1 In the current proposal, we will use systems biological approaches to address two fundamental issues in vaccinology. The first issue concerns the immunology of COVID-19 vaccines, which utilize novel platforms (mRNA) or adjuvants (Matrix M used in the Novavax vaccine). The second…
Mark Morris Davis · STANFORD UNIVERSITY · 2024 · $553,826 — PROJECT SUMMARY In this technology development project, we want to continue the significant progress that we made in this last granting period and take advantage of the many opportunities that we see to make human immune organoids an indispensable system for understanding human immune responses t…
Christian Jobin · UNIVERSITY OF FLORIDA · 2024 · $77,848 — CANCER THERAPEUTICS AND HOST RESPONSE (CTHR) PROGRAM: ABSTRACT The University of Florida Health Cancer Center (UFHCC) CTHR program integrates investigators with expertise in microbiome, immunology, cancer biology, bioengineering, medicinal chemistry, and clinical trial development to advance cancer …
Marie Pancera · FRED HUTCHINSON CANCER CENTER · 2024 · $493,694 — PROJECT SUMMARY/ABSTRACT Broadly neutralizing antibodies are likely to be an important component of an HIV-1 vaccine. The HIV-1 Envelope (Env) glycoprotein is the sole target of neutralizing antibodies and has been a focus of immunogen designs. Yet diverse recombinant (rec) Envs do not display detec…
DREW WEISSMAN · UNIVERSITY OF PENNSYLVANIA · 2024 · $91,182 — SUMMARY – CORE A (Administration Core) The "mRNA Vaccines for C. difficile Suppression” program (mVACS) consists of a highly interactive team of investigators who are seeking to develop an mRNA vaccine platform to provide protection against Clostridioides difficile-associated infection and disease. …
DREW WEISSMAN · UNIVERSITY OF PENNSYLVANIA · 2024 · $311,038 — SUMMARY- PROJECT 1 (VACCINE DEVELOPMENT) Clostridioides difficile is a gram negative spore forming pathogen that causes mild to severe gastrointestinal disorders and death in the elderly, immune compromised individuals and those exposed to systemic antibiotics. Increased recurrence and difficulties …
PAUL JOSEPH UTZ · STANFORD UNIVERSITY · 2024 · $133,135 — PROJECT SUMMARY/ABSTRACT The overarching goal of this R21 proposal is to test the hypothesis that DNA vaccines induce durable innate memory in HIV-infected humans by characterizing the evolution of the epigenetic and transcriptional landscape in subjects who have been immunized using a novel HIV DNA…
CHIUNG-YU HUNG · UNIVERSITY OF TEXAS SAN ANTONIO · 2024 · $1,357,000 — Summary (Overall) San Antonio has a rich tradition of excellence in the field of Medical Mycology, including Coccidioidomycosis, also referred to as Valley Fever. These infections affect hundreds of thousands of healthy and immunocompromised individuals in the endemic areas of the arid Southwest U.S…
Elias Sayour · UNIVERSITY OF FLORIDA · 2024 · $617,119 — Project Summary: Despite standard of care with maximal surgical resection, external beam radiotherapy, and chemotherapy, patients with glioblastoma (GBM) live little more than 18 months after diagnosis; these outcomes necessitate development of new targeted therapies. To address this gap, our group …
Gaurav Das Gaiha · MASSACHUSETTS GENERAL HOSPITAL · 2024 · $859,455 — Modified Project Summary/Abstract Section The development of a prophylactic vaccine for HIV would benefit from the generation of immunogens and vaccine delivery modalities that can induce a combination of highly functional CD8+ T cell responses towards mutation constrained epitopes and broadly neutr…